Urgent action is required to improve efforts to prevent hepatitis B and C infections in the EU/EEA and the UK if the region is to meet the 2020 targets for the elimination of viral hepatitis as a serious threat to public health. Significant gaps in the reported data in relation to prevalence and prevention of HBV and HCV in EU/EEA and the UK present a major challenge to monitoring progress towards the targets for elimination of hepatitis.
Shigellosis is a relatively uncommon disease in the European Union/European Economic Area (EU/EEA), but remains of concern in some countries and for some population groups. For 2017, 30 EU/EEA countries reported 6 337 confirmed shigellosis cases.
In 2018, 37 527 cases of hepatitis C were reported in 29 EU/EEA Member States. The number is 37 427 when countries that only reported acute cases are excluded, which corresponds to a crude rate of 8.8 cases per 100 000 population.
This report provides the first collation of data relating to the monitoring of the progress towards the elimination of hepatitis B and C for EU/EEA countries.
European surveillance data show on-going transmission of viral hepatitis across the European Union and European Economic Area (EU/EEA). The available notification data however, do not provide a clear epidemiological picture of hepatitis C in Europe. Prevalence data from population surveys are a key source of information to complement the surveillance data for hepatitis C due to the limitations of surveillance for hepatitis: the infection is often asymptomatic and notifications are strongly influenced by local testing practices. The overarching aim of this toolkit is to gain a better understanding of the HCV epidemiology in the EU/EEA.